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Placental growth factor  
mediates aldosterone-dependent 
vascular injury
Jaffe et al., J Clin Invest 2010; 120: 3891–3900; doi:10.1172/JCI40205
In clinical trials, aldosterone antagonists were found to reduce 
cardiovascular disease and mortality by magnitudes that were dif-
ficult to ascribe to their modest blood pressure-lowering effects. 
Although these observations generated many hypotheses about 
aldosterone’s potential mechanism of action, no satisfactory 
explanation was advanced, as minimal changes in blood pressure 
can have profound cardiovascular consequences, particularly in 
already diseased blood vessels. However, the in vitro, but robust, 
demonstration that both vascular smooth muscle cells and 
endothelial cells contain mineralocorticoid receptor (MR) as well 
as the cortisol-inactivating enzyme 11β-hydroxysteroid dehydro-
genase-2 suggested that aldosterone may directly regulate blood 
vessel homeostasis. Jaffe et al. recently extended these studies by 
using gene expression profiling to identify aldosterone-regulated 
genes in blood vessels. In aldosterone-stimulated aortas, they 
found substantial induction of placental growth factor (PGF; a 
member of the VEGF family of growth factors), a protein that cir-
culates in plasma, binds to VEGF receptor-1, and promotes pro-
liferation of vascular smooth muscle cells. Aldosterone-mediated 
increases in aortic PGF message, protein, and secretion were all 
inhibited by treatment with the MR antagonist spironolactone. 
The authors also found that in injured blood vessels, aldosterone 
further increased PGF and its receptor. Importantly, although 
the expected vascular smooth muscle proliferation that occurs 
after vascular injury was enhanced by aldosterone (Figure), this 
was not the case in PGF knockout mice. This work thus identi-
fies PGF as a novel downstream target of the vascular MR and 
indicates that this member of the VEGF family contributes to 
aldosterone augmentation of vascular injury.
These findings suggest a nonrenal mechanism for the vascu-
lar protective effects of aldosterone antagonists and support that 
targeting the vascular aldosterone/MR/PGF pathway could be a 
therapeutic strategy in vascular diseases.
Juan Oliver
Epithelial Notch signaling regulates 
interstitial kidney fibrosis
Bielesz et al., J Clin Invest 2010; 120: 4040–4054; doi:10.1172/JCI43025
The most prominent finding in the kidney with end-stage 
disease is tubulointerstitial fibrosis (TIF), where the normal 
epithelial and vascular architecture is replaced by fibroblasts, 
myofibroblasts, and extracellular proteins. Many chronic renal 
diseases can result in TIF, and recent epidemiological stud-
ies indicate that even patients who had a single episode of 
acute kidney injury are at greater risk for TIF development. 
The cellular mechanisms of TIF generation are still not well 
understood. In fact, even the origin of the most abundant cells, 
interstitial fibroblasts and myofibroblasts, is still being debated. 
Myofibroblasts are fibroblast-like cells that express α-smooth 
muscle actin and have increased capacity for production of 
collagen fibrils and matrix. A large body of both in vitro and 
in vivo work strongly suggested that tubular epithelial cells 
(TECs) can transdifferentiate into mesenchymal fibroblasts 
via the process of epithelial–mesenchymal transdifferentiation 
(EMT), giving rise to myofibroblasts and TIF. However, recent 
cell lineage tagging experiments failed to confirm the epithelial 
origin of myofibroblasts but rather indicated that specific inter-
stitial cells proliferate and become activated myofibroblasts, 
causing TIF. In a recent communication, Bielesz et al. report 
that activation of the Notch pathway in TECs plays an impor-
tant role in TIF development. The Notch pathway is a signaling 
mechanism between neighboring cells that consists of several 
receptors, Notch1–Notch4, and their ligands, Delta and Jag-
ged (Jag). Activation of the pathway occurs by expression of 
the ligand in a signal-giving cell, which activates the recep-
tor in the signal-receiving cell and thus induces changes in its 
gene expression. By this ability to distinguish between cells, 
the pathway is critically involved in cell-fate determination. In 
two animal models of TIF and in human kidney samples with 
TIF, Bielesz et al. found increased expression of components 
of the Notch pathway, and inhibitors of its activation amel-
iorated TIF but did not change the increase in serum creati-
nine. In mice with TEC-specific deletion of Notch signaling, 
they found a marked reduction of TIF in response to folic acid 
injury. Importantly, conditional expression (by doxycycline 
administration) of activated Notch1 in vivo in TECs caused 
TIF (Figure). Intriguingly, the in vivo effects of Notch were 
independent of EMT.
In sum, these results demonstrate that activation of 
the Notch pathway in TECs is a critical regulator of TIF 
Aldosterone-enhanced smooth muscle proliferation after vascular 
injury is inhibited in PGF knockout (KO) mice. Medial proliferation 
was quantified in BrdU-stained sections of uninjured (U) and injured 
(I) wild-type and PGF knockout mouse carotid arteries treated with 
vehicle or aldosterone. Medial BrdU labeling data for all animals is 
shown at the top.
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development, but that EMT does not mediate this effect. 
Regardless of its precise mechanism of action, pharmaco-
logical inhibition of Notch activation may represent a novel 
treatment for renal fibrogenesis.
Juan Oliver
m-TOR inhibitors may influence 
nephrin in renal transplants
Biancone et al., Am J Transplant 2010; 10: 2270–2278; doi:10.1111/j.1600-
6143.2010.03259.x
The development of proteinuria in patients with kidney trans-
plants during treatment with m-TOR inhibitors has been 
reported, and some suggest that m-TOR inhibition may alter 
the biology of glomerular podocytes, which could contribute to 
proteinuria. Therefore, Biancone et al. analyzed renal biopsies 
from patients with kidney transplants and evaluated the immu-
nohistological levels of nephrin as a critical component of the 
glomerular slit diaphragm. In biopsies of patients started on de 
novo m-TOR inhibitor treatment, the staining of nephrin within 
glomeruli was significantly reduced in all cases compared with 
pretransplantation donor biopsies. In contrast, nephrin staining 
remained unchanged in transplant biopsies from patients not 
treated with m-TOR inhibitors. In a group of patients initially 
treated without m-TOR inhibitors and subsequently switched 
to m-TOR inhibitor treatment, protocol biopsies performed 
before introduction of m-TOR inhibitors were also available. 
The expression of nephrin in the pre-m-TOR inhibitor biopsies 
was similar to that observed in the pretransplantation donor 
biopsies but was significantly reduced after the introduction of 
m-TOR inhibitors. Proteinuria increased after the initiation of 
m-TOR inhibitors in this group. However, some cases did not 
develop proteinuria, despite reduction of nephrin staining. In 
vitro experiments with cultured human podocytes showed that 
sirolimus downregulated nephrin expression.
The authors interpret their results as suggesting that m-TOR 
inhibitors may reduce podocyte nephrin expression in kidney 
transplants, and that this may be a contributing factor to the 
development of proteinuria that is occasionally observed in 
these patients.
Detlef Schlöndorff
Acetaminophen increases blood 
pressure in patients with coronary 
artery disease
Sudano et al., Circulation 2010; 122: 1789–1796; doi:10.1161/
CIRCULATIONAHA.110.956490
Because of the effects of nonsteroidal anti-inflammatory medica-
tions on renal perfusion, nephrologists commonly recommend 
acetaminophen for pain control. Patients with chronic kidney 
disease (CKD) frequently have coronary artery disease. Although 
the double-blind, placebo-controlled crossover trial by Sudano et 
al. on the effect of acetaminophen on cardiovascular parameters 
was performed in patients with normal kidney function, it still 
provides valuable information about the cardiovascular safety of 
this medication. Thirty-three patients were studied. Subjects were 
randomized to receive acetaminophen (1 g three times a day) or 
placebo for 2 weeks. Multiple cardiovascular parameters were 
measured at baseline and at 2 weeks after the first dose. Subse-
quently, all subjects underwent a washout period and switched 
to the other therapy (placebo or acetaminophen), and all studies 
were repeated at this second baseline and after 2 weeks of the 
second course of therapy. The average age of treated subjects was 
60.5 years, and the average creatinine level was approximately 
1.0 mg/dl. There was no difference between baseline and 2-week 
post-acetaminophen values for endothelial-cell function as meas-
ured by flow-mediated dilatation, circulating endothelial pro-
genitor cells, or platelet function. There also was no difference in 
serum creatinine after treatment. The mean systolic and diastolic 
blood pressures, however, both rose (122.4 ± 11.9 to 125.3 ± 12.0 
mm Hg versus placebo for systolic, 73.2 ± 6.9 to 75 ± 7.9 mm Hg 
versus placebo for diastolic).
It should be underscored that this trial was performed in 
patients with normal kidney function. Therefore, its utility in 
describing the effects of acetaminophen on kidney function 
as well as the potential that the blood pressure changes might 
be amplified in patients with CKD must be considered. How-
ever, it suggests that in a population with significant coronary 
artery disease, the effects of acetaminophen on cardiovascular 
parameters other than blood pressure are negligible. Given the 
obvious downsides of nonsteroidal anti-inflammatory drugs 
with regard to kidney function in patients with CKD, this 
evidence supports the use of acetaminophen in patients with 
both heart and kidney disease.
Lynda Szczech
Transgenic expression of ICNotch1 in tubular epithelial cells (TECs) 
causes severe kidney fibrosis. Dox, doxycycline.
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